Artemis

2015 Nobel Prize in Medicine

WHAT IT IS:
• Artemisinin from Sweet Wormwood extract

WHY YOU NEED IT:
• Supports patients needing therapy for chronic infections such as Lyme disease, Lyme-related co-infections (Bartonella, Babesia, Anaplasma, Rickettsia, Mycoplasma, Chlamydia), chronic viral infections (Epstein Barr, CMV, Herpes), and parasites
• Important adjuvant therapy for patients with cancer
• Targets patients who need powerful immune support
• Great for colon health and hemorrhoid management
• Clinically tested
• Well tolerated, natural therapy

This product can only be purchased by patients.

MORE DETAILS

Artemis
2015 Nobel Prize in Medicine

WHAT IT IS:
• Artemisinin from Sweet Wormwood extract

WHY YOU NEED IT:
• Supports patients needing therapy for chronic infections such as Lyme disease, Lyme-related co-infections (Bartonella, Babesia, Anaplasma, Rickettsia, Mycoplasma, Chlamydia), chronic viral infections (Epstein Barr, CMV, Herpes), and parasites
• Important adjuvant therapy for patients with cancer
• Targets patients who need powerful immune support
• Great for colon health and hemorrhoid management
• Clinically tested
• Well tolerated, natural therapy

HOW IT WORKS:

Artemisinin is an extract from the Chinese herb, Sweet Wormwood, that has been used for over two thousand years in traditional herbal therapy. In the 1960s, a Chinese medical doctor, Dr. Tu, discovered the effectiveness of artemisinin in treating malaria. Artemisinin derivatives are now used around the world to treat malaria, and Dr. Tu received the 2015 Nobel Prize in Medicine for her important work.

Since its discovery, artemisinin and its derivative, Artesunate, have been clinically researched for their uses in other infectious diseases and cancer.

Artesunate IV has been found to be effective support for patients with a variety of bacterial, parasitic, and viral infections. Researchers have also demonstrated anti-tumor effects of Artesunate in some of the most difficult to treat cancer types, including pancreatic cancer, melanoma, colon cancer, leukemia, and liver cancer.

Artesunate IV appears to work by acting as an oxidant, a molecule that causes damage by creating a chemical reaction that permanently damages other molecules. Infectious organisms and cancer cells cannot adequately defend themselves against strong oxidative damage and are killed in the process.

Oxidation occurs every second of every day in your body, and it is one of the most important tools your immune system uses to kill bad bugs and cancer cells.

Normal, healthy body cells can repair oxidative damage, and therefore are largely unharmed during oxidative therapies. This phenomenon allows the safe use of Artesunate IV in patients with chronic infections and cancer.

In laboratory studies, Artesunate IV also has been shown to have effects that are important for patients with growing and metastasizing tumors.

As with all natural products, the sourcing of the material matters greatly. Just because a product has ‘artemisinin’ on the label does not mean that the quality and effectiveness are guaranteed. Only Sweet Wormwood plants grown in special agricultural and geographic locations contain artemisinin.

Artemis has been specifically cultivated and produced to maximize the power of this important herb.

The Artesunate IV is dosed 1-2 times weekly, in treatment cycles of 10 therapy sessions. Each session will include a pretreatment with UVBI/ozone or Major AutoHemotherapy. Next, the Artesunate IV will be administered, followed by some intravenous hydration, and then 25,000mg of Vitamin C IV. A full treatment will take approximately two hours.

To continue the benefits of Artesunate IV, oral artemisinin should be taken daily in liposomal form. Blood tests for liver function and anemia should be checked approximately every 4 weeks to monitor for the possibility of liver irritability and low hemoglobin.

Usual dosage: 3 – 4 droppersfull of Artemis on an empty stomach three times daily.

REFERENCES:
Shoeb, J of ChemoTher 1990; 2(6): 362-367
Crespo-Ortiz, J of Biomed and Biotech Vol 2012, Article ID 247597, 18 pgs
Li, Am J Trop Med Hyg 2009 Oct; 81(4): 615-21
Du, Cancer Chemother Pharmacol 2010 65:895-902
Stockwin, Int J Cancer 2009 Sept 15; 125(6):1266-1275
Efferth, Curr Drug Targets 2006; 7:407-21
Paik, J Med Chem 2006; 49:2731-4
Nam, Head Neck 2007; 29:335-40
Chen, Cancer Chemother Pharmacol 2004; 53:423-432
Chen, Pharmacol 2004; 71:1-9